CO2020002985A2 - Formulaciones tópicas de cloroprocaína - Google Patents

Formulaciones tópicas de cloroprocaína

Info

Publication number
CO2020002985A2
CO2020002985A2 CONC2020/0002985A CO2020002985A CO2020002985A2 CO 2020002985 A2 CO2020002985 A2 CO 2020002985A2 CO 2020002985 A CO2020002985 A CO 2020002985A CO 2020002985 A2 CO2020002985 A2 CO 2020002985A2
Authority
CO
Colombia
Prior art keywords
chloroprocaine
formulations
topical formulations
ophthalmic
abrasions
Prior art date
Application number
CONC2020/0002985A
Other languages
English (en)
Inventor
Augusto Mitidieri
Elisabetta Donati
Clara Bianchi
Original Assignee
Sintetica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sintetica S A filed Critical Sintetica S A
Publication of CO2020002985A2 publication Critical patent/CO2020002985A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RESUMEN Se proporcionan dosis y formulaciones tópicas de cloroprocaína, incluidos geles y ungüentos, y métodos de fabricación y uso de las mismas que son eficaces, químicamente estables y fisiológicamente balanceadas para la seguridad y la eficacia. Las dosis y formulaciones son particularmente útiles durante los procedimientos oftálmicos o en respuesta a abrasiones o traumatismos oftálmicos en función de su tolerabilidad y farmacocinética.
CONC2020/0002985A 2017-09-15 2020-03-13 Formulaciones tópicas de cloroprocaína CO2020002985A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762559220P 2017-09-15 2017-09-15
PCT/IB2018/057073 WO2019053657A1 (en) 2017-09-15 2018-09-14 TOPICAL FORMULATIONS OF CHLOROPROCAINE

Publications (1)

Publication Number Publication Date
CO2020002985A2 true CO2020002985A2 (es) 2020-05-29

Family

ID=63713967

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0002985A CO2020002985A2 (es) 2017-09-15 2020-03-13 Formulaciones tópicas de cloroprocaína

Country Status (23)

Country Link
US (3) US10792271B2 (es)
EP (1) EP3681473A1 (es)
JP (1) JP2020533321A (es)
KR (1) KR20200053476A (es)
CN (1) CN111163756B (es)
AU (1) AU2018332212B2 (es)
BR (1) BR112020003095A2 (es)
CA (1) CA3070336C (es)
CL (1) CL2020000665A1 (es)
CO (1) CO2020002985A2 (es)
CR (1) CR20200133A (es)
CU (1) CU20200019A7 (es)
EA (1) EA202090735A1 (es)
EC (1) ECSP20022313A (es)
IL (1) IL273213A (es)
JO (1) JOP20200010A1 (es)
MA (1) MA50241A (es)
MX (1) MX2020002898A (es)
PE (1) PE20201281A1 (es)
PH (1) PH12020550029A1 (es)
SG (1) SG11202000992RA (es)
WO (1) WO2019053657A1 (es)
ZA (1) ZA202000601B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202139993A (zh) * 2020-03-16 2021-11-01 瑞士商辛鐵堤卡公司 具有經改良之功能性的眼用氯普魯卡因(chloroprocaine)凝膠

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
JP2004123634A (ja) * 2002-10-03 2004-04-22 Lion Corp 眼科用組成物
JP2006513224A (ja) * 2002-12-20 2006-04-20 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ エステル局所麻酔薬の組み合わせ
US20050137177A1 (en) * 2003-12-18 2005-06-23 Shafer Steven L. Ester combination local anesthetic
CA2596194A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
ITMI20051633A1 (it) 2005-09-06 2007-03-07 Sint Sa Nuovo uso di una composizione comprendente cloroprocaina hcl nuova composizione comprendente cloroprocaina hcl e metodo per la sua fabbricazione
CN103405576B (zh) * 2013-08-23 2016-03-30 何学忠 一种治疗由焊接强光辐射引起的眼部疾病的滴眼液

Also Published As

Publication number Publication date
US20240216323A1 (en) 2024-07-04
CA3070336C (en) 2022-08-23
SG11202000992RA (en) 2020-03-30
MA50241A (fr) 2020-07-22
EA202090735A1 (ru) 2020-06-22
PH12020550029A1 (en) 2021-02-08
CL2020000665A1 (es) 2020-09-21
CU20200019A7 (es) 2020-11-30
ECSP20022313A (es) 2020-07-31
BR112020003095A2 (pt) 2020-08-25
CN111163756B (zh) 2022-04-15
PE20201281A1 (es) 2020-11-24
JP2020533321A (ja) 2020-11-19
CA3070336A1 (en) 2019-03-21
CN111163756A (zh) 2020-05-15
CR20200133A (es) 2020-05-09
US10792271B2 (en) 2020-10-06
JOP20200010A1 (ar) 2022-10-30
US11969403B2 (en) 2024-04-30
EP3681473A1 (en) 2020-07-22
WO2019053657A1 (en) 2019-03-21
US20200390738A1 (en) 2020-12-17
IL273213A (en) 2020-04-30
ZA202000601B (en) 2021-02-24
AU2018332212B2 (en) 2023-03-16
AU2018332212A1 (en) 2020-02-27
US20190083446A1 (en) 2019-03-21
MX2020002898A (es) 2020-11-06
KR20200053476A (ko) 2020-05-18

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CR20160130A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso
CL2018000455A1 (es) Miembro de la banda para el uso de máscara de respiración y cuna para la cabeza que incluye el mismo
CR20170492A (es) Composiciones de ácido obeticólico y métodos de uso.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
ECSP21030482A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
CO2020007044A2 (es) Derivados de pirrol como inhibidores de acc
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
CO2018012020A2 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3
CO2020002985A2 (es) Formulaciones tópicas de cloroprocaína
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CY1122755T1 (el) Eξισορροπημενες απο αποψη φυσιολογιας ενεσιμες μορφοποιησεις φωσνετουπιταντης
UY38606A (es) Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas
CL2018002010A1 (es) Derivados de indano y su uso en terapias.
EP3957314A4 (en) USE OF AN EXTRACT FROM VACCINIA VIRUS INFLAMMATED RABBIT SKIN TO TREAT HEMATOPOIETIC SYSTEM DAMAGE
BR112018070603A2 (pt) formulações líquidas de fosfaplatina
BR112021024546A2 (pt) Compostos tricíclicos e uso dos mesmos